杂志名称：Chemistry & Biodiversity
影响因子：2.9
文章题目：Ameliorative Effect of Morinda officinalis oligosaccharides on LPS-induced Acute Lung Injury
DOI：10.1002/cbdv.202400506
第一作者：Cheng Wang, Cheng Qing, Yanrong Wu, Binbin Liu, and zhenguo Zeng
作者单位：
南昌大学江西医学院第一附属医院麻醉与疼痛医学中心重症监护医学系
江西中医药大学附属医院眼科
南昌洪都中医医院重症内科
江西省卫生健康委员会危重症护理医学重点实验室
南昌大学传染病诊断重点实验室
引用YOBIBIO产品：
U96-1494E  Mouse IL-1β ELISA Kit
U96-1511E  Mouse IL-6 ELISA Kit
U96-3112E  Mouse TNF-α ELISA kit

文章摘要：
Acute lung injury (ALI) is a disease characterized by extensive lung damage and rampant inflammation, with a high mortality rate and no effective treatments available. Morinda officinalis oligosaccharides (MOOs), derived from the root of the traditional Chinese medicinal herb Morinda officinalis, known for its immune-boosting properties, presents a novel therapeutic possibility. To date, the impact of MOOs on ALI has not been explored. Our study aimed to investigate the potential protective effects of MOOs against ALI and to uncover the underlying mechanisms through an integrated approach of network pharmacology, molecular docking, and experimental validation. We discovered that MOOs significantly mitigated the pathological damage and decreased the expression of pro-inflammatory cytokines in LPS-induced ALI in mice. Complementary in vitro studies further demonstrated that MOOs effectively attenuated the M1 polarization induced by LPS. Network pharmacology analysis identified HSP90AA1, HSP90AB1, and NF-κB as key overlapping targets within a protein-protein interaction (PPI) network. Furthermore, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses elucidated the biological processes and signaling pathways implicated in MOOs′ therapeutic action on ALI. Subsequently, molecular docking affirmed the binding of MOOs to the active sites of these identified targets. Corroborating these findings, our in vivo and in vitro experiments consistently demonstrated that MOOs significantly inhibited the LPS-induced upregulation of HSP90 and NF-κB. Collectively, these findings suggest that MOOs confer protection against ALI through a multi-target, multi-pathway mechanism, offering a promising new therapeutic strategy to mitigate this severe pulmonary condition.

急性肺损伤(Acute lung injury, ALI)是一种以广泛的肺损伤和猖獗的炎症为特征的疾病，死亡率高，无有效治疗方法。巴戟天寡糖(MOOs)是从传统中药巴戟天(Morinda officinalis)的根中提取的，以其免疫增强特性而闻名，为治疗提供了一种新的可能性。迄今为止，moo对ALI的影响尚未得到探讨。本研究旨在通过网络药理学、分子对接和实验验证的综合方法，探讨MOOs对ALI的潜在保护作用，并揭示其潜在机制。我们发现MOOs可以显著减轻lps诱导的ALI小鼠的病理损伤，降低促炎细胞因子的表达。补充的体外研究进一步证明MOOs可以有效地减弱LPS诱导的M1极化。网络药理学分析发现HSP90AA1、HSP90AB1和NF-κB是蛋白-蛋白相互作用(PPI)网络中的关键重叠靶点。此外，基因本体(GO)和京都基因与基因组百科全书(KEGG)分析阐明了MOOs对ALI治疗作用的生物学过程和信号通路。随后，分子对接证实了MOOs与这些鉴定靶点的活性位点的结合。为了证实这些发现，我们的体内和体外实验一致证明MOOs显著抑制lps诱导的HSP90和NF-κB上调。总的来说，这些发现表明moo通过多靶点、多途径机制对ALI具有保护作用，为减轻这种严重肺部疾病提供了一种有希望的新治疗策略。